Literature DB >> 15567896

Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis.

Narisa Futrakul1, Tasanee Panichakul, Punnee Butthep, Prasit Futrakul, Pim Jetanalin, Suthiluk Patumraj, Prasong Siriviriyakul.   

Abstract

A persistent proteinuria is commonly observed in nephrotic patient with focal segmental glomerulosclerosis (FSGS) under treatment with prednisolone+/-cyclophosphamide or with vasodilators (ACEI+AII receptor antagonist, calcium channel blocker and antiplatelet agent). Fourteen such patients with persistent proteinuria were subject to be treated with Ganoderma lucidum. Initial study revealed an enhanced endothelial cell cytotoxicity induced by patient's serum, and an altered immunocirculatory balance with predominant proinflammatory cytokine TNF alpha activity in the presence of defective anti-inflammatory cytokine interleukin-10. Treatment with Ganoderma lucidum suppressed endothelial cell cytotoxicity, restored immunocirculatory balance and successfully suppressed proteinuria in all of these 14 patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567896

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  3 in total

1.  Urgent call for reconsideration of chronic kidney disease.

Authors:  Narisa Futrakul; Prasit Futrakul
Journal:  World J Nephrol       Date:  2012-12-06

2.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

3.  Suppression of Th17 Cell Response in the Alleviation of Dextran Sulfate Sodium-Induced Colitis by Ganoderma lucidum Polysaccharides.

Authors:  Bing Wei; Ran Zhang; Jingbo Zhai; Junfeng Zhu; Fangli Yang; Dan Yue; Xiaoyi Liu; Changlong Lu; Xun Sun
Journal:  J Immunol Res       Date:  2018-05-20       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.